Definition of dysregulated immune components in multiple sclerosis may help in the identification of new therapeutic targets. Deviation of the interleukin 18 receptor 1 (IL18R1) is of particular interest since the receptor is critical for experimental neuroinflammation. The objective of this study was to determine whether expression of IL18R1 varies between multiple sclerosis patients and controls, and to test genetic association of IL18R1 with multiple sclerosis. We used quantitative real-time PCR to assess mRNA levels of IL18R1 in cerebrospinal fluid and peripheral blood mononuclear cells of 191 patients with multiple sclerosis, 61 patients with clinically isolated syndrome and 168 controls having other neurological disorders. Association was tested in 2153 patients with multiple sclerosis and 1733 controls using 13 tagging single nucleotide polymorphisms within the IL18R1 gene. We found that patients with multiple sclerosis had increased IL18R1 mRNA expression in both cerebrospinal fluid cells (p < 0.05) and peripheral blood mononuclear cells (p < 0.05) compared with controls. Patients with clinically isolated syndrome had elevated levels compared with controls in cerebrospinal fluid cells (p < 0.001) but not in peripheral blood mononuclear cells. The gene was not associated to multiple sclerosis. We conclude that the increased expression of IL18R1 may contribute pathogenically to disease and is therefore a potential therapeutic target. The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with an incompletely defined aetiology. Genetic and environmental components interact to cause inflammation and demyelination with subsequent damage to neurons/axons in affected individuals. 1 Genome-wide and candidate gene association studies have begun to unravel genetic causes of this debilitating disease. The contribution of many inflammatory genes has recently been confirmed. [2] [3] [4] [5] [6] [7] [8] [9] Among MS risk genes are interleukin receptors, namely the interleukin 2 receptor alpha (IL2RA) and the IL7R. [2] [3] [4] Interestingly, all unequivocally defined non-HLA genes detected so far are related to functions in the immune system. However, defined causative agents and critical dysregulation of immune system components still need to be better defined to obtain more selective therapies. 10 The interleukin 18 receptor 1 (IL18R1) was recently identified to regulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. 11, 12 The IL-18 ligand signals through the IL-18R heterodimer, which is part of the IL-1/Toll-like receptor superfamily and consists of the ligand-binding IL18Ra (encoded by the IL18R1 gene) and the signal transducing IL18Rb. The receptor is expressed on astrocytes, macrophages, natural killer (NK), T and dendritic cells. 13 Signalling induces differentiation of T helper1 (T H 1) cells, activation of NK cells and production of T H 17-promoting cytokines by macrophages. 11, 14 Studies of patients with MS have highlighted increased IL-18 ligand levels compared with healthy controls. [15] [16] [17] [18] However, in experimental neuroinflammation the ligand, IL-18, was not necessary for EAE, whereas its receptor was, this suggesting that there are other, not yet defined, ligands to the receptor. Thus, although several studies have measured IL-18 in MS, little is known about the potentially more important receptor in this disease.
We hypothesized that IL18R1 polymorphisms determine susceptibility to MS and that mRNA expression levels distinguish patient and control groups. We tested mRNA expression of IL18R1 in cerebrospinal fluid (CSF) cells and peripheral blood mononuclear cells (PBMCs) of 191 patients with MS, 61 patients with clinically isolated syndrome (CIS) and 168 controls having other neurological disorders (OND). IL18R1 displayed increased mRNA expression in both CSF cells and PBMCs in MS compared with OND controls. Additionally, elevated IL18R1 levels were recorded in CSF cells of CIS patients compared with controls. We also performed a candidate gene association study with 2153 MS patients and 1733 controls, using 13 tagging single nucleotide polymorphisms (SNPs) across the IL18R1 gene, but determined no SNP or haplotype association.
Materials and methods

Patients and controls
All patients fulfilled either the Poser or the McDonald criteria for MS. 19, 20 Information about the study and questions regarding previous participation in studies and ethnic origin of parents were presented to donors both orally and in written form. Oral informed consent was obtained from all patients and controls. Anonymity was maintained throughout material handling and analyses. The local ethical committee in Stockholm, Sweden approved all experiments performed.
The MS cohort for the expression study consisted of 178 relapsing-remitting MS, four primary progressive MS and nine secondary progressive MS patients, all from Karolinska University Hospital in Solna, Sweden. Patients were either untreated (78%) or treated with an immunomodulatory drug (22%), such as interferon-b, copolymer-1 or steroids. In addition, 61 CIS patient samples were collected. The control cohort comprised patients suffering from OND (n ¼ 98) such as headache, migraine or vertigo. Furthermore, additional OND patients had an inflammatory component (OND.INF; n ¼ 70) including systemic lupus erythematosus or post-polio syndrome. Subjects contributed PBMCs and CSF samples.
The association study dataset consisted of 2153 Swedish MS cases and 1733 controls with Scandinavian origin. Some 518 controls and 621 recently diagnosed patients were part of an epidemiological study (EIRA) 21 where patients and controls are matched for sex, age and residency. The rest of the controls (1215) were blood donors (between 21 and 76 years old (median 47 years of age)) and MS cases recruited from MS clinics in Sweden (between 22 and 91 years old (median 53 years of age)). For further details see Roos et al. 22 
Material collection
For the expression study, CSF samples were collected by lumbar puncture and centrifuged (350 g) to pellet the cells. Peripheral blood was sampled in sodium citrate-containing cell preparation tubes (Vacutainer CPT; BD Bioscience, San Jose, CA, USA). PBMCs were separated by density gradient centrifugation, collected and washed twice with phosphate-buffered saline (PBS). Cell pellets were frozen on dry ice and stored at À80 C until use.
For the association study, patient blood was sampled between 1987 and 2008. DNA was isolated from blood using the QIAamp DNA Blood Midi kit (Qiagen) and stored at À80 C until use.
Fluorescently activated cell sorting
PBMCs from five MS patients were isolated as described above. Cell types were labelled with anti-CD3:PE, anti-CD4:PE:Cy5, anti-CD14:FITC and anti-CD19:APC (BD Biosciences, San Jose, CA, USA), respectively, for 20 min at 4 C. Cells were washed twice with PBS and resuspended in 300 ml of PBS before sorting using a MoFlo (Becton Coulter, Fullerton, CA, USA). Approximately 2 Â 10 5 cells of each subpopulation were purified. Cells were spun at 300 g and pellets stored at À20 C until use. Sorting purity was determined to be >95%.
RNA and cDNA preparation
Cell pellets were lysed and total RNA was extracted (PicoPure RNA isolation kit; Arcturus Bioscience, Mt. View, CA, USA). Samples were DNase treated (Qiagen RNase-free DNase set, Hilden, Germany). Reverse transcription of total RNA (1-5 ng) was performed with 0.1 mg random hexamer primers (Invitrogen, Carlsbad, CA, USA) and 200 U Superscript Reverse Transcriptase (Invitrogen). cDNA was stored at À20 C until use.
Quantitative real-time PCR and statistics mRNA expression was determined using the iCycler thermal cycler and the iQ5 Real-Time PCR detection system with SYBR Green as fluorophore (Bio-Rad, Hercules, CA, USA). The primers used for detection of the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase were: forward primer 5 0 AGG GCT GCT TTT AAC TCT GGT AAA and reverse primer 5 0 CAT ATT GGA ACA TGT AAA CCA TGT AGT TG; and for IL18R1: forward primer 5 0 GAG AAA CAT TTT GGG TAT AAG TTA TGC AT and reverse primer 5 0 TTT TCT CTA TCA GTG AGT GGA TTT CAT C. Analysis of targets was performed using the iQ5 Optical System Software v2.0 (Bio-Rad). Quantification was determined using a ratio of IL18R1/GAPDH expression. Group data were analysed using the Kruskal-Wallis analysis of variance followed by a Dunn's post-hoc analysis and correlation was tested using the Spearman's rank test, all in Graph Pad Prism v.5 (Graph Pad, San Diego, CA, USA). Medians are presented.
SNP selection and genotyping
SNP markers were selected for genotyping by running the TAGGER algorithm with r 2 ! 0.9 permitting aggressive two and three SNP tagging 23,24 based on data from the HapMap CEU population (http:// www.hapmap.org, release 21/phaseII, NCBI B35 assembly, dbSNP b125). Allelic discrimination was performed with matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc., San Diego, CA, USA), as described previously. 22 Primer sequences are listed in Table 1 . Genotype calls were manually checked by two independent people using the SpectroTYPER RT 3.3.0 software (Sequenom Inc.). On each 384-well plate analysed as a unit, half of the samples were controls and the remainder were cases. The genotyping was carried out in two separate projects which were run in parallel. The quality control requirements were: Hardy-Weinberg p > 0.01, a concordance rate >95% with known HapMap individual genotypes as well as duplicate DNA and a success rate >80%. DNA quantity was insufficient to test all SNPs completely. Two SNPs (rs6750020 and rs7758013) failed in one of the projects but worked fine in the other, resulting in a low success rate overall. We attempted to genotype these two SNPs with Taqman allelic discrimination, but this was not successful. The success of each SNP genotyping assay was calculated as the number of genotypes retrieved divided by the possible number of genotypes.
Association study and power calculations
Differences in allele frequencies between patients with MS and controls were tested through single marker association analysis using the model commands in PLINK v 1.04. 25 No correction for multiple testing was applied because no SNP was nominally associated. Haplotype association analyses, in blocks with high linkage disequilibrium (LD) as well as for combinations of SNPs that were identified in the tagging analysis to capture the variation in other SNPs, were performed using Haploview 3.32. 26 Haplotype blocks were defined using standard settings (Confidence interval, four gamete rule and solid spine). The power to detect association was estimated using Genetic Power Calculator. 27 Results IL18R1 mRNA expression discriminates patient and control groups IL18R1 mRNA expression was determined with qPCR in CSF cells and PBMCs for patients with MS and demographically matched controls ( Table 2) . Three sub-types of MS patients were compared to determine whether IL18R1 could distinguish between stages of disease. No differences in mRNA expression levels were identified in either CSF cells ( Figure 1A) or PBMCs ( Figure 1B) ; therefore, all patients were combined into a single MS group. In addition, we tested a single Devic's case (neuromyelitis optica), which has similar pathological features to MS, 28 and interestingly determined the highest level of IL18R1 in the CSF of this individual (fivefold higher than the MS median). MS patients (n ¼ 191), CIS patients (n ¼ 61), OND controls (n ¼ 98) and OND.INF controls (n ¼ 70) were compared for IL18R1 mRNA expression. Both MS and CIS patients had increased IL18R1 levels in CSF cells compared with controls (p < 0.05) (Figure 2A ). OND and OND.INF control groups had comparable mRNA levels of IL18R1 in PBMCs, so they were combined in order to increase power. Patients with MS had an elevated expression of IL18R1 mRNA in PBMCs compared with controls (p < 0.05), whereas CIS patients did not ( Figure 2B ). IL18R1 mRNA levels were not affected by any immunomodulatory drugs; treated (n ¼ 42) and untreated (n ¼ 149) MS patients had equivalent levels (data not included). No correlation was identified between IL18R1 expression and CSF cell count, clinical expanded disability status scale score or lesion load measured using magnetic resonance imaging (data not included). We concluded that IL18R1 mRNA levels are increased in CSF cells and PBMC of patients with MS. Additionally, IL18R1 levels may be an early marker of MS because CIS patients, the vast majority of whom will develop MS, 29 had elevated expression levels in CSF cells.
We next investigated the source of IL18R1 mRNA expression using sorted cells. PBMCs from five MS patients were labelled with monoclonal antibodies and sorted using flow cytometry. CSF cells could not be sorted due to low cell numbers. The following subsets were collected: CD3 þ CD4 þ and CD3 þ CD4 À T cells, CD14 þ monocytes and CD19 þ B cells. Both CD3 þ CD4 þ and CD3 þ CD4 À T-cell subsets had high levels of IL18R1 mRNA, while low expression was determined for CD14 þ monocytes and CD19 þ B cells (p < 0.05) (Figure 3 ). T cells are thus the primary producers of IL18R1 in PBMCs. Figure 3 . The primary source of IL18R1 mRNA is T cells. Peripheral blood mononuclear cells from five patients with multiple sclerosis were sorted using flow cytometry, and IL18R1 mRNA expression was determined. CD3 þ CD4 þ and CD3 þ CD4 À T cells had high expression while CD14 þ monocytes and CD19 þ B cells had low levels. The ratio of expression between IL18R1/GAPDH is presented. Significance was determined using a Kruskal-Wallis test followed by a Dunn's post-hoc test. *p < 0.05.
No association between IL18R1 and multiple sclerosis
We had more than 80% power to detect association with an odds ratio (OR) of 1.3 using a dominant model for markers with minor allele frequency of 9% and a success rate of genotyping of 86%. For markers with higher minor allele frequency and better success rate the power to detect association was higher. A tagging SNP approach was used to select representative genotypes across the IL18R1 gene. A LD plot depicts the location of two correlated LD blocks and the 13 selected tag SNPs, which are all located in introns of IL18R1 (Figure 4) . A total of 2153 MS cases and 1733 controls were genotyped; however, rs6750020 and rs77580113 had reduced sample numbers due to lack of some DNA samples. Association was tested using the model functions in PLINK. None of the SNPs significantly associated with disease for any genetic model ( Table 3) .
The LD structure of IL18R1 in our Swedish casecontrol dataset consisting of 3886 individuals is represented for the 13 tag SNPs in Figure 5 . The LD structure is similar to what was observed in the HapMap CEU families (Figure 4 ). Three distinct LD blocks were identified using confidence interval definition of haplotype blocks. There were no significant differences between MS patients and controls in the distribution of haplotypes in the IL18R1 gene (data not included). It is thus unlikely that IL18R1 genotypes confer a significant risk to development of MS in the Swedish population.
Discussion
IL18R1 has recently been shown to mediate EAE through regulation of both IL-18-dependent and -independent pathways, 11, 12 We explored the contribution of IL18R1 to MS, an inflammatory disease syndrome, through gene expression and genetic association studies. We did not find evidence of association between tagging SNPs across the IL18R1 gene and MS. However, we identified up-regulation of IL18R1 mRNA in MS and CIS patients compared with OND and OND.INF controls. Expression of IL18R1 may represent an early event in MS patients, but does not empirically reflect disease course or severity. Our results expand knowledge of the immune system's involvement in regulating MS and provide a new target for treatment development. IL-18 production is dysregulated in both MS [15] [16] [17] [18] and EAE, 30, 31 indicating a role in pathogenesis. IL-18 is produced as a pro-protein that is cleaved by caspase-1 before secretion. 32, 33 IL-18 then binds to IL18R to exert its pro-inflammatory effects. Caspase-1 inhibitors block the initiation of this pathway but also have off-target effects. 34 IL-18 blockade 30 and IL-18-binding protein delivery 35 have also been proposed as therapeutic approaches. However, no effective current therapies target IL-18 directly. Using specific gene-deleted mice, it was demonstrated that IL18R signalling is more important in EAE than IL-18 itself, suggesting another still-unidentified ligand. 11 Therefore, receptor blocking would appear more attractive than therapeutic manipulation of IL-18. Accordingly, monoclonal antibodies against IL18Ra have proven to be effective in ameliorating EAE. 11 Increased mRNA expression of IL18R1 has been previously reported in EAE. 12 Our results now demonstrate increased mRNA expression of IL18R1 in human disease. The IL-18/IL18R pathway offers an exciting opportunity for treatment development.
T cells were determined to be the major source of IL18R1 mRNA expression in our study, concurring with studies demonstrating high IL18R1 levels on CD4 þ T H 1 cells. 36 Furthermore, the CD3 þ CD4 À subset in our analysis, which mainly comprises CD8 þ T cells, had equivalent high IL18R1 expression. MS lesions are predominantly infiltrated by CD8 þ T cells, 37 and these cells can both express IL18R1 and respond to IL-18. 38 The percentage of T cells in CSF and peripheral blood is unlikely responsible for our results because MS patients and controls have similar cell type distributions. 39, 40 NK cells are also known to express IL18R1, 13 although the percentage of this cell type in control PBMCs is low (6%). 41 The PBMCs from MS patients circulate to the CNS and infiltrate during initiation and ongoing disease. We were unable to sort CSF cells due to low cell counts, but we believe that our results from PBMCs are also representative of immune cells in the CNS. However, we cannot exclude the additional contribution of antigen presenting cells, such as dendritic cells, which circulate out of the CNS. 42 It has recently been reported that specific T-cell subsets can direct the regional focus of CNS attack. 43 Interestingly, the single Devic's case in our study had the highest level of IL18R1 in their CSF cells. Further study in a cohort with increased prevalence of this disease subtype may elucidate additional effects of this molecule.
Recent genome-wide and candidate gene association studies have begun to unravel the complexities of MS.
Association has been determined for IL2RA, IL7R, CD58, EVI5, RPL5, IRF8, CD6, TNFRSF1A and CD226. [2] [3] [4] [5] [6] [7] [8] [9] These studies demonstrate that the immune system is not only involved in MS pathology but also plays a causative role, as genetic determinants in immune genes predispose for disease susceptibility. We hypothesized that IL18R1 genotypes also governed disease; however, our candidate gene case-control association study demonstrated no association between IL18R1 and MS. The increased levels of the IL18R1 receptor could be regulated from polymorphisms elsewhere in the genome, or by other factors in the MS inflammatory cascade. However, we had the power to detect OR of 1.3. We cannot exclude that there is a polymorphism with a smaller effect than this in the IL18R1 gene. Although IL18R1 genotypes do not determine susceptibility to disease, IL18R1 levels may be important for disease initiation and ongoing inflammation through increasing T H 1 cell numbers, increasing CD8 þ T-cell activity and promoting T H 17 pathways. 11, 14 IL18R1 increase may be an early feature of MS, and the data here along with previous experimental data on the molecule make it, or pathways controlled by it, interesting for therapeutic targeting in MS.
